SAN FRANCISCO, Sept. 8 /PRNewswire/ -- Takeda San Francisco Inc. announced today that Gregory Landes, Ph.D., has joined the company as vice president of antibody research. Dr. Landes will be responsible for directing the discovery and preclinical development of therapeutic antibodies at Takeda's antibody IND engine and center of excellence for biologics.
"Greg brings over 25 years of experience in the biopharmaceutical industry and is a great addition to the Takeda San Francisco management team," said Mary Haak-Frendscho, Ph.D. president and chief scientific officer, Takeda San Francisco. "Greg's extensive experience covers key aspects of antibody drug discovery and development. He will play an important role as we expand Takeda's biologics R&D capabilities in order to realize our goals of advancing superior therapeutics to contribute to the health of individuals."
Dr. Landes previously has held executive positions with major biopharmaceutical companies, including Lexicon Pharmaceuticals, Abgenix, Inc. and Genzyme Corp, where he led antibody drug discovery, antibody development and functional genomics. He has authored more than 49 peer-reviewed publications and is co-inventor on 12 issued plus additional pending patents. He holds a BA in Chemistry and PhD in Biochemistry from the University of Kansas and was a post-doctoral scholar at UCLA.
About Takeda San Francisco
Takeda San Francisco was established in November 2007 and supports Takeda's therapeutic antibody research aiming to build antibody technology platforms based on technologies such as discovery and development of antibodies, enhancement of antibody activity and antibody-manufacturing in close collaboration with Takeda's other R&D organizations. Additional information about Takeda San Francisco is available at http://www.takedasf.com.
Founded in 1781 and located in Osaka, Japan, Takeda (TSE: 45
|SOURCE Takeda San Francisco Inc.|
Copyright©2008 PR Newswire.
All rights reserved